Tag: Novo Holdings acquisition of Catalent
Novo Holdings to Finalize $16.5B Acquisition of Catalent as FTC Approves Deal
Novo Holdings, the parent company of Novo Nordisk, is set to finalize its $16.5 billion acquisition of Catalent, a prominent contract drug manufacturer, as the U.S. Federal Trade Commission (FTC) greenlights the deal, signaling...
European Regulators Approve $16.5 Billion Novo Holdings Acquisition of Catalent
European Regulators Give Green Light to $16.5 Billion Novo Holdings Acquisition of CatalentIn a groundbreaking move, the European Commission has officially approved the $16.5 billion acquisition of Catalent by Novo Holdings, the parent company...
Catalent’s Deal with Novo Holdings: Customer Reassurance and Updates
Catalent, a major contract drug manufacturer, recently reassured its customers through an open letter that its proposed acquisition by Novo Nordisk’s parent company for $16.5 billion would not impact its ability to provide services...
Opposition Mounts Against Catalent Sale to Novo Holdings: Consumer and Labor Groups Call on...
A group of organizations, including labor unions and consumer advocates, is calling on the Federal Trade Commission to block the acquisition of Catalent, a major contract drug manufacturer, by Novo Nordisk’s parent foundation for...
